Intraoperative Detection of Residual Cancer in Breast Cancer



Status:Recruiting
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:2/10/2019
Start Date:February 6, 2018
End Date:June 2019
Contact:Jorge Ferrer, Ph.D.
Email:jmferrer@lumicell.com
Phone:617-404-1040

Use our guide to learn which trials are right for you!

Feasibility Study Phase C: Expansion Into Multiple Institutions for Training in the Use of the LUM Imaging System for Intraoperative Detection of Residual Cancer in the Tumor Bed of Female Subjects With Breast Cancer

This is a non-randomized, open-label, multi-site study to collect safety and efficacy data on
an intraoperative imaging system, the LUM Imaging System (LUM015 imaging agent in conjunction
with the LUM imaging device), in identifying residual cancer in the tumor bed of female
breast cancer patients. During the study, study physicians and clinical staff will complete
hands-on training in anticipation of the upcoming pivotal study. Site-specific or
user-specific issues related to the use of the device will be identified and addressed.
Additionally, the data collected in the study will be used to continue training the tumor
detection algorithm of the device.

In this study, patients will be injected with LUM015 prior to surgery. The study physicians
will perform lumpectomy procedures according to his or her institution's standard of care
practice. After the main specimen removal is completed, the study physician will use the LUM
Imaging Device to image the tumor bed. Therapeutic shaves will be removed based on the
recommendation of the LUM Imaging System. Patients will be followed until their first
standard of care post-operative follow-up visit.

For breast cancer lumpectomies, the presence of residual cancer cells left in the tumor bed
after initial resection in inferred by post-operative margin assessment of the resected
tissue by a pathologist.

Phase C enrollment will include approximately 5 patients per surgeon, with 2-3 surgeons per
site and up to 20 sites. Subjects undergoing a lumpectomy procedure to treat primary breast
cancer will be injected with a single dose of LUM015 4 ± 2 hours prior to surgery at a dose
of 1.0 mg/kg. The sequence of events during the surgical procedure will vary based on the
standard of care used by the surgeon. Patients will receive at a minimum the standard of care
practices for each site. Lumicell-guided shaved cavity margins will be removed after the
surgeon has attempted to remove the main specimen with grossly negative margins.

Study treatment ends when the surgery is completed. All patients will continue their
enrollment in the study until their first follow-up visit and they will continue to be
followed until the medical team determines no further surgical intervention is required.
Patients with adverse events that are determined to be possibly related to the LUM Imaging
System will be followed until resolution or stabilization of the adverse event.

Inclusion criteria:

- Subjects must have histologically or cytologically confirmed primary invasive breast
cancer, ductal carcinoma in situ (DCIS) or a combination of invasive breast cancer and
DCIS. The protocol accepted methods for obtaining the histological samples are
diagnostic core needle biopsies or fine needle biopsies.

- Female, age of 18 years or older. Because no dosing or adverse event data are
currently available on the use of LUM015 in subjects <18 years of age, children are
excluded from this study.

- Subjects must be scheduled for a lumpectomy for a breast malignancy.

- Subjects must be able and willing to follow study procedures and instructions.

- Subjects must have received and signed an informed consent form.

- Subjects must have no uncontrolled serious medical problems except for the diagnosis
of cancer, as per the exclusion criteria listed below.

- Subjects must have normal organ and marrow function within limits as defined below:

- Leukocytes > 3,000/mcL

- Platelets > 75,000/mcL

- total bilirubin within normal institutional limits

- AST (SGOT)/ALT (SGPT) < 2.5 X institutional upper limit of normal

- Creatinine ≤ 1.5 mg/dL or creatinine clearance > 60 mL/min/1.73 m2 for subjects
with creatinine levels above institutional normal.

Exclusion criteria:

- Subjects who are treated for bilateral breast cancer resection procedure.

- Subjects who are pregnant at the time of diagnosis of their breast cancer; this
exclusion is necessary because the teratogenic properties of LUM015 are unknown.
Because there is an unknown but potential risk of adverse events in nursing infants
secondary to treatment of the mother with LUM015, breastfeeding should be discontinued
if the mother is treated with LUM015.

- Subjects who are sexually active and not willing/able to use medically acceptable
forms of contraception (hormonal or barrier method of birth control, abstinence) upon
entering the study and for 60 days after injection of LUM015. Should a woman become
pregnant or suspect she is pregnant while participating in this study, she should
inform her treating physician immediately. Breast cancer patients are routinely
advised against becoming pregnant during treatment, so this requirement does not
differ from standard of care.

- Subjects who have taken an investigational drug within 30 days of enrollment.

- Subjects with prolonged QTc interval defined as greater than 480 ms.

- Subjects who will have administration of methylene blue or any dye for sentinel lymph
node mapping on the day of the surgery prior to imaging the lumpectomy cavity with the
LUM Imaging Device.

- Subjects who have not recovered from adverse events due to other pharmaceutical or
diagnostic agents.

- Subjects with uncontrolled hypertension defined as persistent systolic blood pressure
> 180 mm Hg, or diastolic blood pressure > 110 mm Hg; those subjects with known HTN
should be stable within these ranges while under pharmaceutical therapy.

- History of allergic reaction attributed to drugs containing polyethylene glycol (PEG).

- History of allergic reaction to any oral or intravenous contrast agents.

- Uncontrolled intercurrent illness including, but not limited to ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, COPD or asthma requiring hospitalization within the past 12 months, or
psychiatric illness/social situations that would limit compliance with study
requirements.

- HIV-positive individuals on combination antiretroviral therapy are ineligible because
of the potential for pharmacokinetic interactions with LUM015.

- Any subject for whom the investigator feels participation is not in the best interest
of the subject.

- Subjects undergoing a second lumpectomy procedure because of positive margins in a
previous surgery prior to entering this study.

- Subjects with prior ipsilateral breast cancer surgeries, mastectomies, breast
reconstructions or implants.

- Subjects who have undergone a surgical biopsy for any reason in the ipsilateral breast
performed less than 2 years prior to enrollment of this study.

- Subjects with prior ipsilateral reduction mammoplasties (breast reductions) performed
less than 2 years prior to enrollment to this study.

- Subjects previously treated with systemic therapies to treat the cancer to be removed
during this clinical investigation, such as neo-adjuvant chemotherapy or hormonal
therapy.

- Subjects undergoing breast conserving surgery whose resected specimen will be
evaluated with frozen section.
We found this trial at
16
sites
Dallas, Texas 75231
?
mi
from
Dallas, TX
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
?
mi
from
Boston, MA
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Burlington, Massachusetts 01805
?
mi
from
Burlington, MA
Click here to add this to my saved trials
Clearwater, Florida 33756
?
mi
from
Clearwater, FL
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
Hershey, Pennsylvania 17033
?
mi
from
Hershey, PA
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
Jacksonville, Florida 32207
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
307 N University Blvd
Mobile, Alabama 36688
(251) 460-6101
University of South Alabama "University of South Alabama is a public institution that was founded...
?
mi
from
Mobile, AL
Click here to add this to my saved trials
333 Cedar St
New Haven, Connecticut 06504
(203) 432-4771
Yale University School of Medicine Founded in 1810, the Yale School of Medicine is a...
?
mi
from
New Haven, CT
Click here to add this to my saved trials
Palo Alto, California 94304
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Royal Oak, Michigan 48073
?
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Tacoma, Washington 98405
?
mi
from
Tacoma, WA
Click here to add this to my saved trials
Troy, Michigan 48098
?
mi
from
Troy, MI
Click here to add this to my saved trials
2025 Frontis Plaza Boulevard
Winston-Salem, North Carolina 27103
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials